申请人:Ranbaxy Laboratories Limited
公开号:EP1958947A1
公开(公告)日:2008-08-20
The present invention relates to inhibitors of phosphodiesterase (PDE) type 4.
Compounds disclosed herein can be useful for treating, preventing, inhibiting or suppressing asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), AIDS, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis or other inflammatory diseases, especially in humans.
Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as phosphodiesterase (PDE) type 4 inhibitors are provided.
本发明涉及磷酸二酯酶(PDE)类型4的抑制剂。本文所披露的化合物可用于治疗、预防、抑制或抑制哮喘、关节炎、支气管炎、慢性阻塞性肺疾病(COPD)、牛皮癣、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合症(ARDS)、艾滋病、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎或其他炎症性疾病,尤其是在人类中。提供了所披露的化合物的制备过程、含有所披露的化合物的药物组合物以及它们作为磷酸二酯酶(PDE)类型4抑制剂的用途。